Careers Investor Relations Education & Training Portal Logins CONTACT PRODUCTS & SERVICES SPECIALTY EXPERTISE CUSTOMER SUPPORT ABOUT US Who We Are Our Inspiration Locations Humane Care Initiative Eureka Science Community Investor Relations News & Events Careers News & Events News & Events Featured Stories Media Coverage Press Releases Conferences Press Resources Media Coverage James Foster Interview on Mad Money with Jim Cramer 09/12/2016 In an exclusive interview, CNBC’s Jim Cramer spoke with James Foster, chairman, president and CEO of Charles River Laboratories, about the Company’s growth plans, drug prices and the future of cancer research. Charles River Laboratories is first CRO to join U.K.-based research consortium 08/22/2016 Charles River Laboratories is the first full-service contract research organization (CRO) to join the U.K.-based, international Milner Therapeutics Institute and Consortium. The Milner Therapeutics Institute and Consortium is a collaborative matchmaking service established in 2015 that connects academic research centers, pharmaceutical companies and the industry’s leading scientists in an effort to accelerate research and improve outcomes for patients. Charles River CEO: 'Companies that don’t grow, die' 06/30/2016 For James Foster, CEO of what is already the second largest Massachusetts-based company in the drug development industry by headcount, Charles River Laboratories, continued growth is a necessity. That mentality has spurred seven acquisitions since 2014. Five Tips to Ensure Your Biomarker Passes Muster 06/27/2016 Widespread adoption of biomarkers has been impeded by a lack of consistent validation methodology and an unclear regulatory environment. If a biomarker is being used to determine the safety and/or effectiveness of a drug, it should be validated rigorously. Here are five key points to consider. The Growing Role of CROs in Cancer Drug Development 06/24/2016 Although cancer’s status as the leading therapeutic area for drug candidates looks set to remain unrivaled for the foreseeable future, the emphasis on each stage of drug discovery and development tends to fluctuate according to each drug maker’s pipeline. Aidan Synnott from Charles River discusses preclinical cancer drug development in Drug Discovery & Development. If I Knew Then... James C. Foster 06/22/2016 Business isn't always perfect. In Crain's "If I Knew Then…" column, Jim Foster discusses what he's learned from his mistakes, including the importance of working with great people. 2016 New Investigator: Hua Wang 06/21/2016 Hua Wang was recently nominated for Bioanalysis Zone's New Investigator Award. Hua is a member of our team in Ohio, and joined Charles River as part of WIL Research this year. He is an outstanding scientist who has contributed significantly to a variety of bioanalysis projects to support drug development programs. Charles River Mulls Moonshots and Mouse Models 05/24/2016 Charles River is conducting new studies using animal models to give insight into therapeutic strategies where pharma companies expect to see the most success. These advances in research models are making “moonshots” a reality for cancer patients. Dr. Joseph Murphy from Charles River discusses more on Outsourcing-Pharma.com. Outsourcing Biosimilars Development 05/17/2016 A rapid increase in the number of companies working on development and registration of biosimilars has created a significant market for outsourced services specific to these products. Biosimilar developers turn to contract organizations when they lack either the internal capability or capacity for conducting certain work as well as when they require additional resources to bring products to market rapidly. Charles River: 2016 to Be ‘Robust Year’ 05/11/2016 After reporting a successful start to FY16, Charles River expects continued success this year driven by customer demand and enhanced strategic partnerships, including expansion of its early stage portfolio. DISPLAYING RESULTS 1-10 (OF 73) |< < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 > >| Contact Us Our experts are available to answer any questions or discuss a quote. From: North America Europe Asia Other Call us at: 1.877.CRIVER.1 (1.877.274.8371) EMAIL US Subscribe to our mailing list to learn about our latest advances: SUBSCRIBE » Careers Press Resources Investor Relations Legal Compliance Policies Connect with Us: RSS Twitter Facebook LinkedIn YouTube © 2021 Charles River Laboratories International, Inc. Legal Terms & Conditions Privacy Policy Products & Services Research Models & Services Drug Discovery Safety Assessment Biologics Testing Solutions Microbial Solutions Avian Vaccine Services Chemicals, Agro & Vet Insourcing Solutions Therapeutic Areas Cardiovascular Central Nervous System Inflammation Metabolic Disease Musculoskeletal Disease Oncology Ophthalmology Respiratory Disease Contact Us Locations Initiate a Project News & Events What's New at Charles River Education & Training Eureka Science Community